A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

Multiple sclerosis (MS), the main central nervous system autoimmune disorder, is the first cause of non-traumatic disability in young adults and has thus significant individual consequences with elevated public health cost. It commonly starts during the third and fourth decades. Over the last twenty years, several disease-modifying therapies with variable benefit/risk profiles have been introduced leading to dramatic changes in the prognosis of MS.
First, several moderately effective therapies , with good safety profile, have allowed to decrease the frequency of relapses along with a possible, albeit limited, effect on medium- and long-term disability.
More recently highly effective therapies (HET), with immunosuppressive properties, have dramatically reduced clinical and MRI disease activity and significantly improved patient's prognosis.
Anti-CD20 therapies (B-cells depleting therapies, given either intravenous or subcutaneous), one of the main HET, have demonstrated higher efficacy than platform therapies in several phase 3 randomized clinical trials and their use within the very first years of the disease seems to be associated with improved long-term outcomes.
Taking all of this into account, the investigators hypothesize that RRMS patients who experience a de-escalation from anti-CD20 therapies to platform therapies after 40 years will not experience disease activity accrual and disability worsening.

Start Date01 Sep 2025

Sponsor / Collaborator

University Hospital of Montpellier

NCT05344469

/ RecruitingNot Applicable

A Non-interventional Study Evaluating Injectable Treatments (Ofatumumab, Glatiramer Acetate and Interferon β1) and Oral Treatments (Teriflunomide, Dimethyl Fumarate and Diroximel Fumarate) in Patients With Relapsing Multiple Sclerosis [AIOLOS]

This is an observational, non-interventional, multicenter, open-label study in patients being treated with any approved injectable or selected oral DMT for RMS in Germany.
Prospective, primary data will be collected via questionnaires and an electronic case report form (eCRF) over a period of up to four years. Additionally, medical history of participants will be collected including disease duration, laboratory values, EDSS, MRI parameters and relapses.

Start Date10 May 2022

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

NCT05688436

/ RecruitingNot Applicable

Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

In this study, researchers will learn more about the effects of diroximel fumarate (DRF), also known as VUMERITY®, when taken during pregnancy in people with multiple sclerosis, also known as MS. In MS, the immune system attacks the nerves in the brain and spinal cord. The affected areas are called lesions. The damage makes it difficult for the brain and spinal cord to function and send messages throughout the body. MS can be a progressive disease, which means it may get worse over time. In relapsing forms of MS (RMS), new symptoms may happen, and existing symptoms may get better or worse over time. DRF is an approved drug that is used to treat people with RMS.
This is known as an "observational" study, which collects health information about study participants without changing their medical care. The main goal of this study is to collect birth and health information from 3 groups of participants and their babies. These groups are:
* Those who took DRF during their pregnancy
* Those who took other drugs for RMS during their pregnancy, but not DRF
* Those who did not take any drugs for RMS during their pregnancy
The main question researchers want to learn about in this study is:
• How many participants' babies were born with major congenital malformations (MCMs)? MCMs are problems with how a baby's body forms before birth.
Researchers will also learn more about:
* Loss of the baby before 20 weeks of pregnancy
* Loss of the baby at and after 20 weeks of pregnancy
* How many babies are born early (at or before 37 weeks)
* How many babies are small for their age while in the participant's uterus
* How many babies are born with any sign of life
This study will be done as follows:
* Participants with RMS can join this study if they become pregnant from 29th October 2019 to 31st July 2030. Information will start being collected when the participant decides to join the study.
* The participants' medical records will be reviewed 2 times during the study - once when the study is halfway done, and one at the end of the study.
* Each participant will be in the study until the end of their pregnancy. Each baby will be in the study for up to 1 year after birth.
* The study is planned to end by 30th April 2031.

Start Date24 Sep 2021

Sponsor / Collaborator

Biogen, Inc.

100 Clinical Results associated with Glatiramer Acetate

100 Translational Medicine associated with Glatiramer Acetate

100 Patents (Medical) associated with Glatiramer Acetate

2,138

Literatures (Medical) associated with Glatiramer Acetate

01 May 2026·Multiple Sclerosis and Related Disorders

Real-world evaluation of the transition between originator and follow-on glatiramer acetate in people with multiple sclerosis: the “GA transition” study

Article

Author: Rasia, Sarah ; Annovazzi, Pietro ; Schiavetti, Irene ; Lus, Giacomo ; Cavalla, Paola ; Pasquali, Livia ; Laroni, Alice ; Sormani, Maria Pia ; La Gioia, Sara ; Carbone, Alessio ; Caleri, Francesca ; Di Sapio, Alessia ; Giovannini, Beatrice ; Signoriello, Elisabetta ; Pozzato, Mattia ; Zecca, Chiara ; Cordioli, Cinzia ; Torri Clerici, Valentina

INTRODUCTION AND OBJECTIVE:

The introduction of follow-on formulations of glatiramer acetate (GA) has raised questions regarding their equivalence to the originator in real-world practice. This study aimed to evaluate the clinical effectiveness and safety of switching from originator GA to its follow-on product, Copemyl® (CO), in people with multiple sclerosis (MS).

METHODS:

A multicenter, retrospective observational study was conducted, including patients with MS treated for at least two years with GA followed by at least two years with CO. The primary outcome was the annualized relapse rate (ARR), whereas secondary outcomes included disability progression assessed by the Expanded Disability Status Scale (EDSS), MRI activity, and adverse events (AEs).

RESULTS:

A total of 138 patients were included. The ARR was very low and comparable across treatments (GA: 0.028; CO: 0.019), with a mean paired difference of -0.009 (95 % CI -0.028 to 0.010; p = 0.38), falling within the predefined equivalence margin. Disability progression over six months occurred in 6.0 % of GA and 7.3 % of CO periods (HR 1.53; 95 % CI 0.74-3.16; p = 0.26). No significant difference was found in MRI activity (52.2 % vs 60.1 %, p = 0.14). Safety profiles were comparable, with mostly mild to moderate AEs; four serious AEs occurred under CO, two of them possibly treatment-related.

CONCLUSIONS:

Switching from originator GA to CO did not influence clinical outcomes or safety. These findings support the therapeutic equivalence of the two formulations in real-world clinical practice, by supporting previous evidence from randomized trials.

01 Mar 2026·INTERNATIONAL JOURNAL OF PHARMACEUTICS

Lyophilized formulation development and characterization of stable glatiramer acetate/oligonucleotide polyplexes at clinically therapeutic strengths

Article

Author: Luan, Xi ; Berkland, Cory J ; Gong, Huan ; Laird Forrest, M ; Daniel Griffin, J ; Abdelaziz, Moustafa M ; Hageman, Michael J

Glatiramer acetate (GA) electrostatically complexes with cytosine-guanine oligodeoxynucleotides (CpG ODN), forming ∼100 nm cationic nanoparticles that localize this potent immunostimulant to the injection site. We previously reported GA-CpG nanoparticles retained the anti-tumor activity of CpG while mitigating systemic immune-related adverse events. Nonetheless, nanoparticulate systems like polypeptide-oligonucleotide complexes pose challenges with reproducible production, in-use stability, and storage stability, which must be solved before translation for clinical use. In this study, we systematically investigated a microfluidic mixing process to define reproducible production of GA-CpG nanoparticles. Dynamic light scattering measurements revealed significantly smaller and more uniform nanoparticles for microfluidic processing versus traditional mixing via pipette. We screened a range of buffer systems to determine the pH and ion types that could maintain colloidal stability and CpG potency. Buffer screening tests indicated that amino acid buffers, particularly glutamic acid, better maintained particle consistency than commonly used parenteral buffers. Finally, formulations of potential lyoprotectants and GA-CpG nanoparticles were developed. Freeze-thaw and freeze-drying experiments were conducted to assess the effects of buffers and lyoprotectants. Formulations with 5% HP-β-CD or trehalose yielded mean particle sizes of less than 127 nm and retained even after storage for 6 months at 40 °C/75% relative humidity. The work on electrostatic complexes reported here may provide valuable guidance to formulators aiming to optimize polypeptide-based oligonucleotide polyplex products for in-use or long-term stability.

01 Feb 2026·Multiple Sclerosis Journal

GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial

Article

Author: Bleich Kimelman, Nadav ; Danon, Uri ; Rubnov, Shai ; Karni, Arnon ; Kolb, Hadar ; Zivadinov, Robert ; Popper, Laura ; Bar-Or, Amit ; Marom, Ehud ; Boyko, Alexey ; Berger, Joseph R ; Miller, Aaron ; Cohen, Jeffrey A

Background::

GA Depot is a long-acting glatiramer acetate (GA)-based formulation designed to provide significantly extended dosing intervals compared to currently available GA formulations.

Objective::

To assess GA Depot efficacy, safety, and tolerability compared to placebo in patients with relapsing multiple sclerosis (RMS).

Methods::

A 52-week multi-center, double-blind, placebo-controlled phase 3 trial in RMS. Patients aged 18–55 with an Expanded Disability Status Scale (EDSS) score ⩽ 5.5 were enrolled and randomized (1:1) to intramuscular (IM) GA Depot 40 mg or matching placebo every 4 weeks. The primary endpoint was annualized relapse rate (ARR) at 52 weeks.

Results::

A total of 1016 patients were treated with GA Depot ( n = 508) or placebo ( n = 508). Adjusted ARR was lower in patients treated with GA Depot compared to placebo (0.18, 95% confidence interval [CI] = 0.14 to 0.3 vs 0.26, 95% CI = 0.21 to 0.32, 30.1% relative risk reduction, p = 0.0066). GA Depot significantly reduced the number of contrast-enhancing lesions ( p = 0.0083). The most common adverse events were injection site reactions (46.1% with GA Depot vs 28.7% with placebo), primarily mild and self-limited.

Conclusion::

GA Depot effectively reduced clinical and radiological activity compared to placebo in RMS patients, recapitulating the favorable profile of subcutaneous GA products with significantly less frequent injections.

Trial Registration::

ClinicalTrials.gov Identifier: NCT04121221 ( https://clinicaltrials.gov/study/NCT04121221 ).

151

News (Medical) associated with Glatiramer Acetate

16 Apr 2026

·www.globenewswire.com

Mapi Pharma to Present Efficacy (EDSS) Data from Glatiramer Acetate Depot Long-Acting Injection Studies in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS) at AAN 2026

Poster scheduled for presentation on Tuesday, April 21, 8:00 AM - 9:00 AM CDTNESS ZIONA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will present efficacy data from GA Depot clinical studies in patients with relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) at the American Academy of Neurology (AAN) Annual Meeting 2026, to take place April 18-22, 2026, in Chicago IL. Mapi’s Glatiramer Acetate Depot (GA Depot) is a long-acting injection version of the approved Glatiramer Acetate (GA, commercially available as Copaxone®) for treating multiple sclerosis (MS), a chronic inflammatory, demyelinating disease characterized by neurological disability accumulation over time. GA Depot was clinically evaluated for RMS which is characterized by inflammatory attacks (relapses) on the central nervous system, causing new or worsening neurological symptoms followed by partial or full recovery and PPMS which is characterized by continued worsening neurologic function from the onset of symptoms, without early relapses or remissions. EDSS (Expanded Disability Status Scale) assessments were collected from two prospective GA Depot clinical studies: an up to three year, open-label, Phase IIa study in PPMS patients (n=30), and a one-year, double-blind, placebo-controlled, pivotal Phase III study in RMS patients (n=1,016 of which n=508 were in the active arm). GA Depot is administered intramuscularly (IM) once every 28 days for both indications at different dosages. In the above studies in PPMS and RMS, GA Depot showed EDSS stabilization, irrespective of baseline EDSS scores. These EDSS findings suggest GA Depot’s potential in slowing disability progression, reinforcing its role in MS management. GA Depot is in a final review process in Germany for the RMS indication and is planned to start a global Phase III study for PPMS. Mapi received the Israeli Ministry of Health’s GMP (Good Manufacturing Practice) approval, enabling commercial launch in RMS in 2027 in Germany and in EU countries and initiation of marketing early 2028. Ehud Marom, Chairman and Chief Executive Officer, Mapi Pharma, said, “We are very excited to share these positive results for GA Depot in the treatment of MS, where there are significant unmet medical needs. The data we are presenting this week at AAN demonstrate that GA Depot can significantly impact disease progression and we believe that this product, once approved, has the potential to transform the treatment landscape for MS. We look forward to further evaluating GA Depot in the clinic in the PPMS indication and are currently seeking a co-marketing partner for GA Depot for the RMS indication in the EU.” The GA Depot data will be featured in a poster GA Depot (long-acting IM glatiramer acetate) and its impact on EDSS in Relapsing forms of Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS) on Tuesday, April 21, 8:00 AM - 9:00 AM CDT (Poster Neighborhood 19 P7: Multiple Sclerosis: Clinical Trials 1, McCormick Place West, Hall F). Company management will be available for one-on-one meetings during the conference to discuss potential joint development collaborations. Interested parties should contact Mapi directly. About Mapi Pharma Mapi Pharma (Mapi) is a clinical stage pharmaceutical company, engaged in development of high barrier-to-entry and high added-value life cycle management ("LCM") products and AB Rated Depot injectable products that target large markets that include complex active pharmaceutical ingredients ("APIs") and formulations. Mapi is developing depot long-acting injections for the anti-psychotic Cariprazine and for the GLP-1’s, Semaglutide and Tirzepatide for diabetes and weight management as well as a generic AB rated version for Naltrexone (Vivitrol®). The Company is also marketing its own generic versions of Fingolimod (Gilenya®) and Apremilast (Otezla®) in specific geographic markets. Mapi is built on strong chemical and pharmaceutical R&D and clinical development capabilities and a deep understanding of the global market and of regulatory needs. Mapi is a global company with a dedicated long-acting depot R&D laboratory and aseptic depot manufacturing and a Fill & Finish for injectable Finished Dosage Forms. Mapi has strong IP positions, numerous granted patent applications for APIs and mainly formulations. For more information, please visit www.mapi-pharma.com Contacts: Alex MogleVice President, Corporate DevelopmentMapi Pharma+972 52 6080297alex@mapi-pharma.com Brian RitchieManaging DirectorLifeSci Advisors, LLCbritchie@lifesciadvisors.com

Clinical ResultPhase 2Phase 3

06 Apr 2026

·allsci.com

Quantum Bio filed IND for Lucid-MS to start Phase II in multiple sclerosis

Canada-based Quantum BioPharma (Nasdaq: QNTM) submitted an IND application to the US FDA for Lucid-21-302, known as Lucid-MS, a small-molecule drug candidate intended for the treatment of multiple sclerosis, according to a company announcement. The submission supports a planned Phase II clinical trial, with an FDA response anticipated in Q2 2026. Multiple sclerosis affects approximately 2.8 million people worldwide, according to the Atlas of MS Third Edition published via PubMed Central. The disease is characterized by immune-mediated attacks on the myelin sheath surrounding nerve fibers, leading to progressive neurological disability. Despite more than two decades of drug approvals, the existing treatment landscape is dominated by agents that suppress or modulate immune activity — interferons, glatiramer acetate, S1P receptor modulators, anti-CD20 antibodies — none of which directly target the demyelination process itself. The absence of any approved remyelination or myelin-protective therapy represents the field’s most persistent gap, particularly for patients with progressive forms of the disease where immune-targeting drugs offer limited benefit. Lucid-MS is described by Quantum BioPharma as a patented new chemical entity designed to inhibit demyelination and provide neuroprotection. The company has not disclosed a specific molecular target or mechanism beyond the functional characterization of myelin preservation; no INN or chemical identifier has been made public. The company positions the compound as mechanistically distinct from approved disease-modifying therapies, arguing that it addresses neurodegeneration directly rather than upstream immune dysregulation. In preclinical models, the company states the compound prevented and reversed myelin degradation, though the full preclinical dataset has not been published in a peer-reviewed forum. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

INDPhase 2

06 Apr 2026

·www.biospace.com

Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors

BOSTON, April 06, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced the appointment of Jon Congleton, an accomplished biopharmaceutical executive, to its Board of Directors (the “Board”). Mr. Congleton currently serves as Chief Executive Officer and Board Member of Mineralys Therapeutics, Inc. (“Mineralys”), which he has led from its founding as a private, early-stage organization through its evolution into a publicly traded, pre-commercial stage biotechnology company. “We are delighted to welcome Jon to Avalyn’s Board, adding another accomplished biopharmaceutical leader with proven experience building and scaling both private and public companies,” said Lyn Baranowski, Chief Executive Officer of Avalyn. “His distinguished track record in commercial strategy and organizational leadership will be instrumental as we advance our Phase 2 programs, MIST for AP01 and AURA for AP02, and prepare for late-stage development and commercialization. Jon’s insights will help us efficiently execute our mission to deliver a new standard of care for patients with pulmonary fibrosis through targeted, better-tolerated inhaled therapies.” “I am thrilled to join Avalyn’s Board and collaborate with such a talented and mission-driven team,” said Mr. Congleton. “Pulmonary fibrosis remains a devastating disease with limited treatment options and significant unmet need. It is truly distressing to understand how few patients with this deadly diagnosis are able to tolerate the existing oral medicines, underscoring the potential Avalyn has to transform standard of care in pulmonary fibrosis given the encouraging clinical data across its two lead programs.” Mr. Congleton brings nearly 40 years of biopharmaceutical experience, with deep expertise in cardiovascular, gastrointestinal, and central nervous system (“CNS”) therapeutic areas, and a consistent focus on delivering innovative solutions for patients and their care partners. He has served as Chief Executive Officer for both private and public companies, demonstrating success in general management, global strategic marketing, brand development, corporate financing, and organizational leadership. Mr. Congleton currently serves as Chief Executive Officer and Board Member of Mineralys, a publicly traded biotechnology company focused on aldosterone-driven cardiorenal conditions. Prior to Mineralys, he served as Chief Executive Officer and Board Member of Impel Pharmaceuticals, a CNS-focused biotechnology company advancing novel upper nasal cavity drug delivery. He was also previously the Chief Executive Officer and a Board Member at Nivalis Therapeutics. Earlier in his career, he held roles of increasing responsibility at Teva Pharmaceuticals, where he was a member of the original U.S. launch team for Copaxone ® in multiple sclerosis, led the Canadian and U.S. Teva Neuroscience businesses, and ultimately oversaw the global CNS franchise. Mr. Congleton holds a B.S. in marketing from Kansas State University. About Avalyn Pharma Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (“PPF”). AP01 has demonstrated encouraging tolerability and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone data. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (“IPF”). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver dual antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies. For more information, please visit avalynpharma.com and follow the company on LinkedIn . Investor Contact: Cassie Saitow, Avalyn Pharma Inc. Sr. Director, IR and Corporate Communications ir@avalynpharma.com Media Contact: Kat Lippincott, Deerfield Group kat.lippincott@deerfieldgroup.com media@avalynpharma.com

Phase 2Executive Change

100 Deals associated with Glatiramer Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D04318	Glatiramer Acetate	L03AX13	DB05259

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Multiple Sclerosis	United States	Teva Pharmaceuticals USA, Inc.	28 Jan 2014
Multiple Sclerosis, Relapsing-Remitting	United States	Teva Pharmaceuticals USA, Inc.	20 Dec 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple sclerosis relapse	Phase 3	United States	Mapi-Pharma Ltd.	19 Sep 2019
Multiple sclerosis relapse	Phase 3	Belarus	Mapi-Pharma Ltd.	19 Sep 2019
Multiple sclerosis relapse	Phase 3	Bosnia and Herzegovina	Mapi-Pharma Ltd.	19 Sep 2019
Multiple sclerosis relapse	Phase 3	Bulgaria	Mapi-Pharma Ltd.	19 Sep 2019
Multiple sclerosis relapse	Phase 3	Estonia	Mapi-Pharma Ltd.	19 Sep 2019
Multiple sclerosis relapse	Phase 3	Israel	Mapi-Pharma Ltd.	19 Sep 2019
Multiple sclerosis relapse	Phase 3	Moldova	Mapi-Pharma Ltd.	19 Sep 2019
Multiple sclerosis relapse	Phase 3	Russia	Mapi-Pharma Ltd.	19 Sep 2019
Multiple sclerosis relapse	Phase 3	Ukraine	Mapi-Pharma Ltd.	19 Sep 2019
Rhabdomyosarcoma	Phase 3	United States	Mapi-Pharma Ltd.	19 Sep 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


P8-6.018 (AAN2024)	Phase 3	Multiple sclerosis relapse	-	GA Depot	uowzblgaaf(fuyswvbcuj) = tjajneczfd bpuufhsmva (qnxckspjjr ) View more	Positive	09 Apr 2024
				Copaxone	uowzblgaaf(fuyswvbcuj) = iqkaxvbygn bpuufhsmva (qnxckspjjr ) View more
S31.010 (AAN2024)	Not Applicable	Multiple Sclerosis	930	Fingolimod	aqiwuzmdar(uzpmtxndqj) = tmnchhqgzx twvcyypuuh (hdljesjxti )	Negative	09 Apr 2024
				Natalizumab	aqiwuzmdar(uzpmtxndqj) = ekvgufgrdy twvcyypuuh (hdljesjxti )
Phase III Open Label period (ACTRIMS2024)	Phase 3	-	821	Glatiramer Acetate Depot	kxehfusxdk(skswdfclua) = The most frequent TEAEs reported (≥5% of the subjects in any treatment group), irrespective of the relatedness, were ISRs, pyrexia, influenza-like illness, body temperature increase, and headache qszfzvjffp (dfcgdueahl ) View more	Positive	29 Feb 2024
				Placebo
GA Depot, Phase 3 (ACTRIMS2024)	Phase 3	Multiple sclerosis relapse	763	GA Depot	ysthrieiai(ohzchzhzui) = mean percent change 8.34 mwrrojysbz (ikiornqkba )	Positive	29 Feb 2024
NCT04121221 (ECTRIMS2023)	Phase 3	Multiple sclerosis relapse	-	GA Depot	eppextiozn(kgyiampgmh) = bvthynxajx yyojkaxbct (vafyzhzkmg ) View more	-	30 Sep 2023
				Copaxone®	eppextiozn(kgyiampgmh) = xcuvinopcc yyojkaxbct (vafyzhzkmg ) View more
AAN2022	Phase 2	Multiple Sclerosis, Relapsing-Remitting anti-GA antibodies	-	GA Depot 80mg	glohcynhcc(laopolspes) = jumciygisi nsphwedhjl (epzivvbehh, +/ - 1.13) View more	Positive	03 May 2022
				GA Depot 40mg	glohcynhcc(laopolspes) = idhatjedau nsphwedhjl (epzivvbehh, +/ - 1.25) View more
NCT00176592 (BECOME, CTgov)	Phase 4	Multiple Sclerosis \| Multiple Sclerosis, Relapsing-Remitting	75	Betaseron (Betaseron)	fyjedxftgt(kqjyisqcsz) = phcbaswotg pofuxhfhbl (acwlamydyc, 2.76) View more	-	16 Nov 2021
				Copaxone (Copaxone)	fyjedxftgt(kqjyisqcsz) = ysehdemyxg pofuxhfhbl (acwlamydyc, 2.46) View more
NCT00326625 (CTgov)	Phase 2	Amyotrophic Lateral Sclerosis	366	Placebo	ekwoeqkmgx(fxdofnfuhg) = kexitkvkob rnbsajihiv (omrnpnkenn, 0.058) View more	-	20 Oct 2021
GA Depot phase IIa (ECTRIMS 12020 \| ECTRIMS 22020 \| AAN2020)	Phase 2	Multiple Sclerosis, Primary Progressive	11	GA Depot	hbdktcxlkv(jobqiwtamx) = stable xnxfswgypd (xrjsyajwuk ) View more	Positive	07 Dec 2020
NCT00211887 (CombiRx, Pubmed \| Neurology)	Phase 3	Multiple Sclerosis	959	Interferon-beta-1a	btrxuaphvk(iydvkzvbio) = After adjustment, anxiety (hazard ratio [HR] 1.25, 95% confidence interval [CI] 1.01-1.55) and dyslipidemia (HR 1.32, 95% CI 1.01-1.72) were associated with an increased hazard of any disease activity, while migraine (HR 0.80, 95% CI 0.67-0.97) was associated with a decreased hazard. jfdqghyolv (fehvsywqcq )	Positive	04 Aug 2020
				Glatiramer acetate

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis